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ABSTRACT
Background: The efficacy of paclitaxel-coated
balloons (PCB) for restenosis prevention has been
demonstrated in humans. However, the mechanism of
action for sustained drug retention and biological
efficacy following single-time drug delivery is still
unknown.
Methods and results: The pharmacokinetic profile
and differences in drug concentration (vessel surface vs
arterial wall) of two different paclitaxel coating
formulations (3 µg/mm
2) displaying opposite solubility
characteristics (CC=crystalline vs AC=amorphous) were
tested in vivo and compared with paclitaxel-eluting
stents (PES). Also, the biological effect of both PCB
formulations on vascular healing was tested in the
porcine coronary injury model. One hour following
balloon inflation, both formulations achieved similar
arterial paclitaxel levels (CC=310 vs AC=245 ng/mg;
p=NS). At 24 h, the CC maintained similar tissue
concentrations, whereas the AC tissue levels declined by
99% (p<0.01). At this time point, arterial levels were
20-fold (CC) and 5-fold (AC) times higher compared to
the PES group (p<0.05). At 28 days, arterial levels
retained were 9.2% (CC) and 0.04% (AC, p<0.01) of the
baseline levels. Paclitaxel concentration on the vessel
surface was higher in the CC at 1 (CC=36.7% vs
AC=13.1%, p<0.05) and 7 days (CC=38.4% vs AC=11%,
p<0.05). In addition, the CC induced higher levels of
neointimal inhibition, fibrin deposition and delayed
healing compared with the AC group.
Conclusions: The presence of paclitaxel deposits on
the vessel surface driving diffusion into the arterial
tissue in a time-dependent fashion supports the
mechanism of action of PCB. This specific
pharmacokinetic behaviour influences the patterns of
neointimal formation and healing.
INTRODUCTION
Paclitaxel-coated balloons (PCB) have
emerged as a viable therapeutic alternative for
the interventional treatment of vascular
disease.
1–5 With the use of this technology, the
short-term transfer and long-term retention of
paclitaxel to the arterial wall is feasible,
16thus
potentially reducing the untoward effects of
the prolonged drug release associated with
polymer-based stent technologies
7–9 including
delayed vessel healing, potentially resulting in
stent thrombosis. Experimental data have
shown that some paclitaxel formulations are
rapidly transferred to the vessel wall following
balloon dilation.
10 11 However, it has been sug-
gested that long-term tissue retention is
affected by the drug morphology and resulting
solubility attained during the coating process.
12
First-generation PCB technologies dis-
played a high level of crystallinity on the
coating surface and were associated with
inconsistent drug load and high particulate
KEY MESSAGES
What is already known about this subject?
▸ The efficacy of paclitaxel-coated balloons (PCB)
for restenosis prevention has been demonstrated
in humans. However, the mechanism of action
for sustained drug retention and biological effi-
cacy following single-time drug delivery is still
unknown.
What does this study add?
▸ Our data suggest that the observed tissue half-
life of paclitaxel delivered by PCB technologies
is rate limiting and relates to the slow dissol-
ution of paclitaxel deposits from the vessel
surface into arterial tissue in a time-dependent
fashion.
How might this impact on clinical practice?
▸ This experimental study provides better under-
standing of the processes of paclitaxel local
delivery which may implicate in the refinement
of currently available and development of new
treatment technologies and options for athero-
sclerotic vascular disease.
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Interventional cardiologyshedding during balloon inﬂation. New generations of
PCB coatings are under development, displaying more
consistent, uniform and less crystalline (CC) coating
characteristics. Although these technological changes
may potentially affect clinical outcomes, the resulting
biological effects on paclitaxel uptake and vessel healing
are still unknown.
At the present time, a potential mechanism of action
explaining long-term drug retention yielding sustained
biological efﬁcacy following single-time drug delivery has
not been described. In this study, we compared the
impact of two different coating types on tissue transfer,
retention and biological efﬁcacy and propose a mechan-
ism of action explaining the durability of the biological
effect following single-time delivery of paclitaxel via
balloon delivery.
METHODS
Device description
PCB angioplasty catheters were prepared having two dis-
tinct drug solid-state morphologies using identical
balloon platforms and paclitaxel-iopromide coating con-
centrations applied at a total drug dose of 3 µg/mm
2.
The solution was precisely metered onto all surfaces of
the balloons, including within the folds. As a conse-
quence of the proprietary controlled drying process fol-
lowing balloon coating, the resulting paclitaxel
morphologies were either substantially amorphous (AC)
or dihydrated CC. The morphological form of the
coating was conﬁrmed by surface electron microscopy
and Raman spectroscopy (ﬁgure 1). The comparison
paclitaxel-eluting stent (PES) used in this study was the
commercially available balloon-expandable TAXUS
Liberté stent system (TS, 3×15 mm, Boston Scientiﬁc,
Natick, Massachusetts, USA) coated with a durable poly-
meric coating formulation containing paclitaxel at a con-
centration of 1 μg/mm
2.
Study schematic
The study scheme is presented in ﬁgure 2. In the ﬁrst
paclitaxel tissue transfer study, abdominal aortas of 44
white rabbits were enrolled. In the following vascular
response experiment, 12 domestic swine (DS) were
included. The description of each study section is pro-
vided below.
Pharmacokinetic studies
All animals received standard care outlined in accord-
ance with the act of animal welfare and the ‘Principles
of Care of Laboratory Animals’.
13 Abdominal aortas of
44 New Zealand white rabbits, either gender, 3.3–4.5 kg,
were treated with a single 3.5×20 PCB each at 1.2–1.3:1.0
overstretch ratio for 60±1 s. An antimicrobial (enroﬂoxa-
cin, 13.5–17 mg/kg), an antispasmodic (Nifedipine,
30 mg) and aspirin 81 mg were given pre procedure.
Induction of anaesthesia was achieved with ketamine/
xylazine (42–45.5/8.75–9 mg/kg) followed by 0–5% iso-
ﬂurane propofol (2–8 mg/kg). Arterial access was
obtained using a surgical cut down technique of the
Figure 1 Top panel: surface electron microscopy pictures of crystalline (left) and amorphous (right) coatings based on an
identical paclitaxel-iopromide combination. Bottom panel: Raman spectroscopy analysis of both coatings.
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Open Heartcarotid artery. Anticoagulation with heparin was
achieved during the procedure to maintain an activated
clotting time ≥250 s. Treated vessels (four per time
point and group) were harvested after 1 h, 24 h, 7 and
28 days. Harvested vessels included the 20 mm treated
segment and 10 mm untreated vessel proximal and
distal to the treated segment in order to facilitate hand-
ling without damaging the treated segment. Taxus stents
(3×15 mm) were used for comparison in the same
model and treated vessels were harvested at 24 h, 7 and
28 days. The total paclitaxel vessel concentration was cal-
culated as a sum of endoluminal and intramural pacli-
taxel amount divided by total vessel weight prior
scraping. The compartmental concentration was calcu-
lated as a paclitaxel amount in the endoluminal and
intramural compartment divided by the weight of tissue
after scraping.
Quantification of paclitaxel surface deposition
The vessel segment was blotted dry of blood, weighed,
carefully incised longitudinally and pinned open, and
stents, if present, carefully removed. The vessel surface
(endoluminal) paclitaxel was removed together with the
entire intimal and endothelial layer from the underlying
muscular and adventitial layers of the vessel segment
(intramural) by gentle scraping with a blunt plastic
pipette. The intima and pipette tip were transferred to a
labelled cryovial. The remaining vessel was weighed
again and transferred to another labelled cryovial. The
cryovials were ﬂash frozen and stored at −70°C prior to
analysis for paclitaxel content. Paclitaxel concentrations
in the intimal and underlying tissues were determined
separately by an independent laboratory using validated
liquid chromatography-mass spectrometry (LC-MS)/MS
methods. Tissues were sectioned into small pieces and
weighed. Samples were then homogenised in phosphate
buffered homogenisation solution. The homogenate was
labelled with an internal standard, extracted with methyl
tert-butyl ether and evaporated to dryness. The reconsti-
tuted sample was analysed by reverse-phase high-
performance LC with MS/MS detection. The total
paclitaxel vessel concentration was calculated as a sum
of endoluminal and intramural paclitaxel amount
divided by total vessel weight prior scraping. The com-
partmental concentration was calculated as a paclitaxel
amount in the endoluminal and intramural compart-
ment divided by the weight of tissue after scraping. Drug
elimination (kelimin) was calculated based on the
following formula kelim=[ln(Cpeak)–ln(Ctrough)]/tinterval.
Second, paclitaxel half-life was calculated t½=0.693/kelim.
Coronary porcine study
All animals received standard care outlined in accord-
ance with the act of animal welfare and the ‘Principles
of Care of Laboratory Animals’.
13 A total of 12 castrated
male DS (mean body weight 40.5±2.4 kg) were included
and maintained on a standard chow diet until comple-
tion of the study. One intramuscular muscarinic anti-
cholinergic dose (glycopyrrolate 0.005–0.02 mg/kg) was
given pre procedure. Induction of anaesthesia was
achieved with a rapid acting general anaesthetic
(Tiletamine+Zolazepam, Telazol 2–5 mg/kg) followed by
Figure 2 Flow chart describing
the study’s designs including
follow-up times. DS, domestic
swine; AC, amorphous; CC,
crystalline; PCB, paclitaxel-coated
balloon; POBA, plain balloon
angioplasty; OCT, optical
coherence tomography; IVUS,
intravascular ultrasound.
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Interventional cardiologyendotracheal intubation with a continuous inhalation of
1–3% isoﬂurane. Arterial access was obtained using a
surgical cut down technique of the carotid artery. All
animals received 75 mg aspirin and 75 mg clopidogrel
3 days before the procedure and continued until com-
pletion of the study. Anticoagulation with heparin was
achieved during the procedure (3000–10 000 U) to
maintain a coagulation time ≥250 s. Following baseline
angiography, a total of 32 coronary arteries were ana-
lysed using intravascular ultrasound to determine the
diameters of the coronary target sites. Coronary predila-
tion was performed using a regular angioplasty balloon
before stent implantation. Then, balloon-expandable
bare metal stents (Orbus X, Bavaria Medizin
Technologie GmBH 3 and 3.5×15 mm) were deployed at
a 1.25:1 overstretch ratio for 30±3 s. Finally, stents were
dilated with one of the PCB formulations (CC or AC) or
a bare balloon was used to postdilate the stents for 30
±3 s ensuring at 1:1 PCB ratio. At 28 days follow-up, all
animals underwent terminal angiography and optical
coherence tomography (OCT) imaging analysis.
Quantitative coronary angiography was performed
ofﬂine by a single operator blinded to the study group
utilising QAngio XA Software V.7.1.14.0 (Medis Medical
Imaging Systems, Leiden, The Netherlands).
OCT imaging
OCT images were recorded using the M4 OCT imaging
system (ImageWire, LightLab Imaging, Inc, Westford,
Massachusetts, USA). Integrated OCT image analysis
software developed by LightLab Imaging was used for all
measurements. System calibration of the z-offset was per-
formed on each image wire before every single imaging
procedure. OCT imaging pullbacks were performed at a
rate of 10 mm/s using continuous non-occlusive
contrast-saline mixture as a ﬂush. All images were
acquired at 100 frames/s and stored on the system hard
drive for off-line analysis. Morphometric analysis was per-
formed by two operators blinded to the study groups.
Each individual pullback analysis was divided into prox-
imal reference vessel, stent segment and distal reference
vessel. Instent analysis was divided into 7–8 equal cross
sections.
Histology protocol
Hearts were removed immediately following termination
and arteries were ﬂushed with Ringer’s lactate for
15 min (1 L). After all the blood was washed out, pres-
sure perfusion ﬁxation was performed for 20 min with
10% neutral buffered formalin. The ﬁxated heart was
immersed in a formalin ﬁlled container for at least 24 h
to continue further ﬁxation. Coronary arteries were
removed from the myocardium and then dehydrated,
embedded in plastic and ﬁnally sectioned at proximal,
mid and distal locations of the stented segment. Each
segment was sectioned for staining. One set of sections
was stained with H&E and a second set with elastin tri-
chrome stain. Using Spot Advanced V.4.1.1 Software
(Spot Imaging Solutions, Sterling Heights, Michigan,
USA), digital vessel images were captured and histomor-
phometry was performed using NOVA PRIME V.6.70.10
software (Bioquant Image Analysis Corp., Nashville,
Tennessee, USA). The Morphometric characteristics that
were evaluated were lumen (L) area (mm
2), internal
elastic lamina (IEL) area (mm
2), external elastic lamina
area (mm
2), medial area (mm
2), per cent area stenosis
and neointimal thickness. Neointimal area was deﬁned
as IEL minus L. Percentage area of stenosis was calcu-
lated as [(IEL−L)/IEL]×100. A semiqualitative score was
used to determine loss of endothelialisation (0=≥90% of
luminal surface covered, 1=75–90% of luminal surface
covered and 2=≤75% of luminal surface covered),
inﬂammation (0=none, 1=mild and 2=severe), medial
smooth muscle cell (SMC) loss (0=none, 1=1–25%,
2=26–50%, 3=51–75%, 4=76–100%) and IEL disruption
(0=none, 1=1–25% and 2=26–50%).
Statistical analysis
Quantitative data were normally expressed as mean value
±SD. For a skewed distribution, data were expressed as
median and IQR. Qualitative data were presented as
number and percentage. The Shapiro-Wilk test was used
for testing normality. Quantitative data were compared
either with the Student t test or one-way analysis of vari-
ance (ANOVA) for normal distribution data or the
Mann-Whitney U test, otherwise. Holm Sidak
post-ANOVA tests were used to test for differences in vari-
ables between stent types. When either equal variance
test or normality test failed, a Kruskal-Wallis test (with
Dunn’s method for post hoc group comparison) was con-
ducted; p values of ≤0.05 were considered statistically sig-
niﬁcant. Areas under the curve (AUCs) were calculated
with the trapezoidal rule and compared utilising method-
ology by Hanley and McNeil.
14 SigmaStat V.3.11 (Systat
Software) and MedCalc V.10.2 (Mariakierke, Belgium)
were utilised for the statistical analyses.
Figure 3 Graphic representation of the 28-day paclitaxel
tissue levels of both paclitaxel-coated balloon coatings in
comparison with the Taxus stent (PES). AC, amorphous; CC,
crystalline; PES, paclitaxel-eluting stent.
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Tissue pharmacokinetics study
Abdominal aortic tissue was harvested at different time
points following either PCB dilation or TS implantation.
The arterial tissue pharmacokinetic proﬁle of all tested
groups is shown in ﬁgure 3. The overall vessel size was
comparable among all groups and the paclitaxel tissue
concentrations were normalised by total tissue weight
(data not shown). Following PCB dilation, the 1 h total
paclitaxel tissue concentrations were comparable with
CC and AC. At 24 h, CC sustained similar concentra-
tions, whereas levels declined by 99% in AC group
(p<0.01). In addition, at the same time point, both the
CC (20-fold) and AC (5-fold) formulations displayed
higher total paclitaxel tissue concentrations compared
with the TS group (p<0.05). Within 7 days, there was a
signiﬁcant decline (CC=88.6% and AC=99.9%) in the
total paclitaxel tissue concentrations compared with ori-
ginal 1 h concentration. In comparison, in the TS group
there was an almost sixfold increase in the total pacli-
taxel tissue concentration at the same time point. In all
groups, paclitaxel tissue levels remained detectable up
to 28 days. The CC group resulted in tissue concentra-
tions threefold higher than the TS group. Conversely,
the AC group yielded paclitaxel tissue concentrations
signiﬁcantly lower and barely detectable when compared
with the CC and the TS groups. Area under the pharma-
cokinetic curve was signiﬁcantly higher in the CC group
as compared with AC and PES (2422.7 vs 138.4 vs
102.45; p<0.05). The calculated tissue half-life for pacli-
taxel delivered by the CC and the AC was 7.5 and
3.4 days, respectively.
Paclitaxel vessel surface deposition analysis
A compartmental vessel analysis (vessel surface vs arterial
wall) was performed by scraping the vessel surface of the
treated segments. In the CC group, paclitaxel concentra-
tions were higher on the vessel surface when compared
with arterial wall concentrations at 24 h, 7 and 28 days
(ﬁgure 4A). Furthermore, AUC for vessel surface pacli-
taxel concentration was signiﬁcantly higher than the
arterial wall level curve (AUC surface: 7118.8 vs
intra-arterial: 1948.1, p=0.03). Conversely, in the AC
group, the vessel surface and the arterial wall concentra-
tions were similar at 1 and 24 h (ﬁgure 4B). After 24 h,
the vessel surface concentration declined further in com-
parison with the arterial wall levels (ﬁgure 4B). The
AUCs for paclitaxel concentration were similar for both
compartments in this group (AUC surface: 127.5 vs
intra-arterial: 190.2; p=0.2). Additionally, at 1 h, the total
vessel surface paclitaxel presence appeared similar.
However, at 24 h and at 7 days, the CC group retained a
higher percentage of the initial paclitaxel uptake when
compared with the AC group. A paclitaxel deposits distri-
bution analysis is shown in ﬁgure 5. This analysis demon-
strated that approximately 27% of the total amount of
drug delivered via balloon dilation remained on the
surface of the vessel regardless of the coating type. At
24 h, 36.7% of the total paclitaxel recovered remained on
the vessel surface in the CC group, compared with 13.1%
in the AC group (p<0.01). In the CC, the vessel surface
deposits of paclitaxel remained stable up to 7 days, while
these deposits further decreased in the AC group (38.4%
vs 11%; p=0.07). At 28 days, the percentage of paclitaxel
vessel surface deposits appeared to equalise between
both groups. The calculated paclitaxel half-life for both
compartments was similar in the AC group (2.5 days for
vessel surface and intra-arterial). By contrast, in the CC
group, the calculated vessel surface half-life was higher
(11.5 days) compared with arterial wall (7.5 days).
Tissue effects coronary study
A summary of the imaging results is presented in
table 1. At baseline, the reference vessel diameter and
the stent:artery ratios were comparable between groups.
The ﬁnal minimal lumen diameter following stent
implantation was also similar between groups. At 28-day
follow-up, the CC group displayed larger minimal lumen
diameters and lower percentage diameter stenosis com-
pared with the AC and the bare balloon control groups.
In the OCT in vivo evaluation, the CC group displayed
larger lumen areas (increase=63.8% vs AC and 45.9% vs
plain balloon angioplasty (POBA); p=0.03) and lower
Figure 4 Compartmental analysis displaying the paclitaxel
concentrations on the inner layer (endoluminal) and
intra-arterial over time (crystalline (A) and amorphous (B)
coatings).
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vs POBA; p=0.03, table 2). In addition, OCT analysis
showed that the distribution of neointima in the AC
group was similar to that in the POBA control group
(ﬁgure 6). Conversely, the CC group displayed a pattern
of neointimal distribution that was heterogeneously dis-
tributed. A summary of the histological ﬁndings is
shown in table 2 and representative stent cross sections
in ﬁgure 7. Similar to the OCT ﬁndings, morphometric
evaluation showed that the CC had 23.7% and 22.2%
decrease in per cent area stenosis when compared with
the AC and the POBA control group, respectively. The
CC group displayed signs of drug effect such as slightly
lower endothelialisation scores, less mature neointima
and higher degrees of ﬁbrin deposition in comparison
to the AC and the POBA control groups.
DISCUSSION
The concept of developing a balloon-based drug deliv-
ery system to prevent arterial restenosis was based on the
hypothesis that a durable effect on neointimal prolifer-
ation could be achieved following the single-time deliv-
ery of paclitaxel into the vessel wall.
1261 5This early
hypothesis contradicted previous experimental
16 and
clinical
17 data suggesting that sustained tissue exposure
to paclitaxel was necessary to effectively decrease resten-
osis. Owing to its unique delivery mechanism and pro-
posed pharmacokinetic proﬁle, the early promising
clinical results of PCB technologies were originally
challenged.
18
Early experimental data conﬁrmed that paclitaxel
transfer into the vessel wall occurs rapidly following
balloon inﬂation.
61 9In addition, tissue pharmacokinetic
Figure 5 Paclitaxel endoluminal
amount over time expressed as
percentage of total vessel
amount. AC, amorphous; CC,
crystalline.
Table 1 Intravascular and angiographic imaging analyses at baseline and at 28-day follow-up following PCB delivery in
porcine coronary arteries
Crystalline coating (n=8) Amorphous coating (n=9) POBA control (n=9)
QVA
Baseline
RVD (mm) 3.09±0.1 3.00±0.1 3.05±0.1
Stent to artery ratio 1.46±0.1 1.35±0.1 1.48±0.1
Balloon to artery ratio 1.46±0.1 1.41±0.1 1.46±0.1
Poststent MLD (mm) 3.28±0.2 3.08±0.3 3.13±0.2
OCT
28-day follow-up
RVD (mm) 2.69±0.3 2.65±0.2 2.60±0.2
MLD (mm) 1.62±0.6 1.41±0.3 1.25±0.7
Diameter stenosis (%) 38.8±24 46.9±10. 51.8±25
Lumen area (mm
2) 5.08±0.8* 2.76±0.28 3.1±2.3
Stent area (mm
2) 10.65±0.4 9.12±0.3† 10.45±1
Neointimal area (mm
2) 5.57±0.7 6.36±0.3 7.20±1.8
Area stenosis (%) 53.1±14* 69.7±11 71.2±18
Neointimal thickness (mm) 0.63±0.1 0.80±0.1 0.80±0.2
*p<0.05 vs Amorphous and POBA.
†p<0.05 vs Crystalline and POBA.
MLD, minimal lumen diameter; OCT, optical coherence tomography; PCB, paclitaxel-coated balloons; POBA, plain balloon angioplasty;
QVA, quantitative vessel analysis; RVD, reference vessel diameter.
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10 showed that short-term tissue levels of pacli-
taxel following balloon delivery were higher by several
orders of magnitude compared with drug-eluting
stents
20 21 and that therapeutic concentrations of pacli-
taxel were found beyond 28 days following initial drug
delivery.
5 Also, several publications demonstrated that
the long-term vessel healing proﬁle appears to be similar
to commercially available drug eluting stent technolo-
gies.
22 However, despite its documented clinical efﬁcacy
in selected clinical scenarios, a potential mechanism of
action explaining long-term drug retention and sus-
tained biological effect has not been proposed for PCB
technologies. In these series of experimental studies, we
propose a working hypothesis for the mechanism of
action of PCB by comparing the pharmacokinetic
behaviour of two different coatings displaying opposite
solubility proﬁles with a commercially available PES.
Paclitaxel transfer and retention
In the present study, paclitaxel tissue levels shown in the
TS group followed a typical pattern of drug release from
a polymer reservoir and the levels progressively increased
from 24 h to 28 days (6-fold and 18-fold increase in tissue
levels at 7 and 28 days, respectively). Data reported from
a similar study in rabbit iliac arteries using TS
23 demon-
strated that paclitaxel tissue concentration increased
from 0% at implant to approximately 5% at 30 days, and
then decreased slowly through 180 days. Therefore, we
chose 1, 7 and 28 days to model TS tissue paclitaxel
increase to peak concentration. In contrast, paclitaxel
transferred to the vessel wall via both PCB formulations
was ∼20 orders of magnitude higher compared with the
early TS tissue levels (ﬁgure 3). At 24 h, the tissue levels
achieved by PCB using the CC remained stable.
Conversely, in the AC group, there was a sharp decline in
paclitaxel tissue levels achieving values comparable to the
TS group. In the AC group, tissue paclitaxel levels contin-
ued to decline over time and fell below the TS curve at
28 days. Conversely, although CC tissue levels steadily
continued to decline, the 28-day tissue levels achieved
were comparable to the TS group. This ﬁnding may
explain the lack of efﬁcacy of some PCB technologies in
early clinical trials.
24 Our data also suggest that acute
drug transfer and long-term tissue retention are inde-
pendent of each other as both PCB formulations
achieved comparable acute transfer levels but very differ-
ent long-term tissue retention levels. In our study, the cal-
culated tissue elimination half-life of total paclitaxel in
treated arteries was several orders of magnitude higher
Table 2 Histomorphometric and vascular healing response analysis of stents according to the PCB formulation used at
28 days
Crystalline coating (n=9) Amorphous coating (n=9) POBA control (n=8) p Value
Morphometric analysis
EEL area (mm
2) 11.54±2.3 9.53±1.2 10.03±1.3 0.054
IEL area (mm
2) 9.29±1.5* 7.53±1.1 7.85±1.4 0.026
Lumen area (mm
2) 4.25±1.9* 2.15±1.4 2.47±2.0 0.046
Medial area (mm
2) 2.24±1.1 2±0.3 2.17±0.6 ns
Neointimal thickness (μm) 588±232 750±210 759±283 ns
Per cent area stenosis (%) 54.8±18* 71.8±15 70.4±20 0.05
Histological analysis
Injury score 1.73±0.6 1.88±0.7 2.11±0.8 ns
Peri-strut inflammation 2.27±0.8 2.32±0.7 2.15±1.1 ns
Adventitial inflammation 1.44±0.7 1.93±0.4 1.79±1.1 ns
Peri-strut granuloma 2.52±0.9 2.74±0.6 2.42±1.1 ns
Endothelial coverage 2.63±0.5 2.85±0.4 3 ns
Fibrin deposits 1.15±0.7* 0.15±0.3 0 <0.01
Neointima maturity 2.41±0.5* 2.96±0.1 3 <0.01
Neointima hypocellularity 0.37±0.5 0.11±0.2 0 ns
Media hypocellularity 0 0.04±0.1 0 ns
*p<0.05 vs Amorphous coating and POBA.
EEL, external elastic lamina; IEL, internal elastic lamina; PCB, paclitaxel-coated balloons; POBA, plain balloon angioplasty.
Figure 6 Neointimal distribution along the treated arterial
segments by optical coherence tomography at 28 days in the
tissue effects arm of the study. PCB, paclitaxel-coated
balloon; POBA, plain balloon angioplasty.
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Interventional cardiology(3.4 for AC and 7.5 for CC) compared with previous
experimental pharmacokinetic studies of paclitaxel deliv-
ered via balloon in which tissue elimination half-life is
reported to be on the order of hours.
12 25–28 This pro-
longed elimination half-life of paclitaxel suggests an add-
itional mechanism for long-term retention through the
development of compartments or deposits from which
drug releases over time into the tissue.
Vessel surface paclitaxel deposits and tissue retention
In this study, we also demonstrated that following PCB
dilation, a proportion of the paclitaxel is retained on the
vessel surface and is not acutely dissolved into the tissue.
In the CC group, sustained paclitaxel vessel surface
levels were maintained, while in the AC group, the
surface concentrations rapidly decreased over time. It
seemed apparent that arterial wall levels of paclitaxel
were driven by the sustained retention of drug on the
surface of the vessel wall, thereby maintaining a positive
concentration gradient from the vessel surface into the
arterial wall. By 24 h the differences in paclitaxel vessel
surface levels were striking between both PCB groups.
However, by 7 days arterial tissue concentrations began
to equalise the vessel surface levels providing an explan-
ation about the lack of tissue toxic effects seen in experi-
mental studies despite the apparent supratherapeutic
tissue levels found immediately after PCB use.
561 12 9At
30 days, the arterial tissue levels of paclitaxel seen in the
CC group were comparable to the levels seen in the TS
group and within the inhibitory concentration range of
SMC proliferation.
30 In addition, the concentration of
paclitaxel found on the vessel surface in the CC group
at the same time point was threefold higher than the
arterial wall levels of the drug. These results seem to be
consistent with previous reports showing that speciﬁc
binding to intracellular proteins occurs primarily in the
subintimal space and determines arterial transport prop-
erties and microtubule binding of paclitaxel.
31 32
Therapeutic window of PCB delivery
Our data suggest that the observed tissue half-life of pacli-
taxel delivered by PCB technologies is rate limiting and
relates to the slow dissolution of paclitaxel deposits from
the vessel surface into arterial tissue in a time-dependent
fashion. Once paclitaxel is transferred into the vessel
wall, the mechanisms of intra-arterial transfer follow well-
described patterns of pharmacokinetics.
33 In any case,
the resulting tissue levels of paclitaxel at 28 days are
above the reported IC50 values for human SMC (1.4–
2 ng/g)
30 and endothelial cell proliferation (1.7–6.8 ng/
g).
34 Thus, the proposed mechanism of action reconciles
the apparent contradiction between the observed short-
term supratherapeutic tissue levels seen right after
balloon delivery and the resulting vessel healing proﬁles
seen at the experimental level. The ‘total’ paclitaxel
levels measured in pharmacokinetic tissues are likely
magniﬁed due to the higher concentrations of non-
soluble paclitaxel deposits remaining on the surface.
These deposits, important as a reservoir to maintain long-
term tissue levels, appear to get washed off into the blood
stream within the ﬁrst 7 days following initial drug deliv-
ery. Then, the resulting levels of intra-arterial paclitaxel
appear to be within the therapeutic range for inhibition
of smooth muscle proliferation and below cytotoxic con-
centrations, which is consistent with experimental and
clinical data, both for peripheral and coronary territory,
on safety and efﬁcacy reported to date.
1–41 5
Biological response to paclitaxel transfer
The differences in paclitaxel tissue retention found in
both PCB groups resulted in signiﬁcant differences in
the degrees of neointimal formation between both
groups. In general, the pattern of drug release and
retention displayed by the CC group resulted in higher
total vessel luminal areas, heterogeneity of neointimal
formation, SMC loss and ﬁbrin deposits. In addition, in
vivo OCT analysis demonstrated a more heterogeneous
Figure 7 Representative histological pictures of CC (A) and AC (B) at 28 days in porcine coronary arteries following
paclitaxel-coated balloon delivery.
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Open Heartpattern of neointimal formation in the CC group. In
conclusion, in these series of studies, we demonstrated
that the type of paclitaxel coating impacts the degree of
drug transfer and retention. Long-term paclitaxel reten-
tion appears to depend on surface deposits that serve as
delivery mechanism occurring over time.
Study limitations
The main limitation of this study derives from its experi-
mental nature and the analytical methods used. First,
the normal rabbit aorta lacks the biological components
seen in atherosclerotic vascular disease. Therefore, the
pharmacokinetic results found in our studies may not
correlate with the levels potentially found in humans. It
is well known that there is a signiﬁcant amount of vari-
ability seen in pharmacokinetic studies using animal
models. In addition, since efﬁciency of removal of insol-
uble drug by the surface wipe technique is not perfect,
the obtained values may introduce analytical errors and
may not reﬂect accurate values for the percentage of
total drug in the surface deposition study. However, all
studies were performed following identical protocols
and procedures introducing the same systematic errors,
if any. Finally, the stent study used a different animal
species (porcine) and slightly higher balloon to artery
ratio than commonly performed in the experimental
setting. Although this approach was used in order to
increase the biological response to drug delivery and
healing, it is known that this method may introduce sig-
niﬁcant variability of the resulting data. Importantly,
since each PCB uses different manufacturing
methods
2361 01 51 6resulting in different coating
characteristics, the results of the present study may not
be directly representative of all PCB technologies.
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